Pfizer Inc.
Methods for purifying FXa variant proteins

Last updated:

Abstract:

Compositions are provided comprising recombinant variants of the human clotting Factor Xa. Such compositions include a wide variety of isoforms and post-translational modifications of FXa and are useful for treating subjects in need of hemostasis.

Status:
Grant
Type:

Utility

Filling date:

4 Aug 2017

Issue date:

26 May 2020